| Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells M Momeny, F Moghaddaskho, NK Gortany, H Yousefi, Z Sabourinejad, ... Scientific Reports 7 (1), 44075, 2017 | 34 | 2017 |
| Blockade of nuclear factor-κB (NF-κB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells M Momeny, H Yousefi, H Eyvani, F Moghaddaskho, A Salehi, F Esmaeili, ... The international journal of biochemistry & cell biology 99, 1-9, 2018 | 33 | 2018 |
| Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells M Momeny, Z Sabourinejad, G Zarrinrad, F Moghaddaskho, H Eyvani, ... Scientific reports 7 (1), 45954, 2017 | 32 | 2017 |
| Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells M Momeny, G Zarrinrad, F Moghaddaskho, A Poursheikhani, ... Scientific Reports 7 (1), 4204, 2017 | 30 | 2017 |
| Systems biology approach identifies prognostic signatures of poor overall survival and guides the prioritization of novel bet-chk1 combination therapy for osteosarcoma PH Pandya, L Cheng, MR Saadatzadeh, K Bijangi-Vishehsaraei, S Tang, ... Cancers 12 (9), 2426, 2020 | 12 | 2020 |
| Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells M Momeny, H Eyvani, F Barghi, SH Ghaffari, S Javadikooshesh, ... Anti-Cancer Drugs 29 (10), 1011-1020, 2018 | 12 | 2018 |
| Precision medicine highlights dysregulation of the CDK4/6 cell cycle regulatory pathway in pediatric, adolescents and young adult sarcomas F Barghi, HE Shannon, MR Saadatzadeh, BJ Bailey, N Riyahi, ... Cancers 14 (15), 3611, 2022 | 5 | 2022 |
| Integrative multi-OMICs identifies therapeutic response biomarkers and confirms fidelity of clinically annotated, serially passaged patient-derived xenografts established from … PH Pandya, AJ Jannu, K Bijangi-Vishehsaraei, E Dobrota, BJ Bailey, ... Cancers 15 (1), 259, 2022 | 4 | 2022 |
| BET inhibitor increases DNA damage, modulates Wnt signaling, and suppresses osteosarcoma growth in naïve and metastatic disease models N Riyahi, PH Pandya, BJ Bailey, EA Dobrota, C Young, HE Shannon, ... Cancer Research 84 (6_Supplement), 3953-3953, 2024 | | 2024 |
| Targeting CDK4/6 and BET proteins for the treatment of RB+ and RB-osteosarcoma R Malko, PH Pandya, HE Shannon, BJ Bailey, EA Dobrota, C Young, ... Cancer Research 84 (6_Supplement), 5719-5719, 2024 | | 2024 |
| Therapeutic Targeting of the Cell Cycle in Pediatric, Adolescent and Young Adult Osteosarcoma F Barghi | | 2024 |
| Therapeutic targeting of BET bromodomain proteins increases DNA damage and potentiates salvage therapy in osteosarcoma xenografts derived from patients with replication stress … N Riyahi, PH Pandya, BJ Bailey, EA Dobrota, C Young, HE Shannon, ... Cancer Research 83 (7_Supplement), 6727-6727, 2023 | | 2023 |
| Osteosarcoma patient-derived xenografts derived from naive and pretreated metastatic patients with high-risk CDK4/6 hyperactivation signatures are sensitive to dual inhibition … F Barghi, MR Saadatzadeh, E Dobrota, R Malko, BJ Bailey, C Young, ... Cancer Research 83 (7_Supplement), 6728-6728, 2023 | | 2023 |
| CDK4/6 inhibitor resistance in relapsed RB-proficient osteosarcoma patient-derived xenografts via PI3 Kinase/mTOR inhibition F Barghi, PH Pandya, MR Saadatzadeh, K Bijangi-Vishehsaraei, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
| Therapeutic induction of replication stress in the context of salvage therapy in osteosarcoma N Riyahi, PH Pandya, MR Saadatzadeh, K Bijangi-Vishehsaraei, ... Cancer Research 82 (12_Supplement), 2017-2017, 2022 | | 2022 |
| Targeting CDK4/6 inhibitor resistance in relapsed RB-proficient osteosarcoma patient-derived xenografts via PI3 Kinase/mTOR inhibition F Barghi, PH Pandya, MR Saadatzadeh, K Bijangi-Vishehsaraei, ... Cancer Research 82 (12_Supplement), 2011-2011, 2022 | | 2022 |
| Targeting CDK4/6 inhibitor resistance in relapsed osteosarcoma via PI3 Kinase inhibition F Barghi, PH Pandya, MR Saadatzadeh, K Bijangi-Vishehsaraei, ... Cancer Research 81 (13_Supplement), 3043-3043, 2021 | | 2021 |
| DNA Repair Defects in Sarcomas N Riyahi, MR Saadatzadeh, K Bijangi-Vishehsaraei, F Barghi, PH Pandya, ... DNA-Damages and Repair Mechanisms, 2020 | | 2020 |
| Inhibition of BET bromodomains reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells M Momeny, F Barghi, H Eyvani, F Esmaeili, Z Alishahi, K Alimoghaddam, ... CANCER SCIENCE 109, 502-502, 2018 | | 2018 |
| Oncologists Annual Meeting H Yousefi, M Momeny, Z Alishahi, A Poursheikhani, H Eyvani, ... | | 2017 |
